RxDoctor Payments Data

Cheryl Kollman, NP

Family · Columbus, OHNPI 1902828338

Payments from drug & device makers

$14,173in general payments, 2019–2025

Across 746 payments — averaging $19.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Xeris Pharmaceuticals, Inc.$2K
  • Dexcom, Inc.$1K
  • Lilly USA, LLC$923
  • Amgen$892
  • Abbott$829
  • Novo Nordisk$782
  • plus $7K from 52 others

What the payments were for

  • Food & beverage$13,92298%
  • Education$310%
  • Other$2202%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,173 in reported general payments places this provider in the 95th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$80,023
Medicare patients
370
Services billed
2,282

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide165$293,462
Humalog Kwikpen U-200Insulin Lispro60$263,990
TrulicityDulaglutide102$154,700
MounjaroTirzepatide123$146,921
JardianceEmpagliflozin87$121,089
FarxigaDapagliflozin Propanediol102$118,136
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/794$111,445
Tresiba Flextouch U-200Insulin Degludec56$92,571
Teriparatide16$45,651
VascepaIcosapent Ethyl49$42,051
Soliqua 100-33Insulin Glargine/Lixisenatide33$39,653
Novolog FlexpenInsulin Aspart103$38,354
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog12$37,363
Gvoke Hypopen 2-PackGlucagon60$36,906
TradjentaLinagliptin31$35,221

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Fiasp, Rybelsus, Novolog$782$365,979248 claims
Lilly USA, LLCTrulicity, Mounjaro, Humalog, Insulin Lispro$923$327,754317 claims
Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr$407$172,802136 claims
AstraZenecaFarxiga$238$118,136102 claims
Sanofi-aventis U.S. LLCSoliqua 100-33, Admelog$316$49,81747 claims
MerckJanuvia$88$31,87228 claims
AbbVieSynthroid$252$8,80691 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,812 family providers in Ohio.

Other family in Columbus

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →